Overview
Ockham is a Global Contract Research (CRO) and Functional Service Provider (FSP) organization headquartered in Cary, North Carolina (near the university-biotech-pharmaceutical sciences nexus known internationally as Research Triangle Park). Satellite offices strategically placed around the United States, in India and the U.K. underpin Ockham’s global customers and operations.
Ockham provides high-quality, global clinical research and strategic development services to pharmaceutical and biotechnology companies, assisting them in the achievement of their strategic planning, technology transfer, licensing, regulatory planning and submissions, pre-clinical development, and manufacturing goals.
Ockham also provides fully integrated clinical trials support in the areas of Clinical Operations, Data Management and Biostatistics, as well as Regulatory dossier compilations. In addition, it offers functional and specialty resourcing services to pharmaceutical, biotech and medical device companies that require Clinical Operations, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), or Good Manufacturing Practice (GMP) auditing, Data Management, Statistical Programming, Biostatistics, and Medical Writing solutions.
Ockham currently operates two distinct business lines:
- Full-Service Contract Research – Ockham is a full-service CRO offering complete Data and Clinical services, including complete Phase I-IV Clinical Trial Management services (full-service or functionally based): Project Management, Clinical Monitoring, Data Management, Biostatistics and Programming, Medical Writing, Regulatory Consulting/Liaison, and Pharmacovigilance (PVG).
- Functional Service Provider - Ockham offers clients Data (SAS® / Statistics / Data Management) and Clinical (Clinical Research Associates/Monitoring, Medical Writing, PVG) – typically based in Ockham offices. Fixed-bid or Time-and-Materials (T&M) pricing models are available. Dedicated, flexible teams allow longer-term relationships with research-critical personnel and eliminate co-employment.
Ockham is fully compliant with U.S. Code of Federal Regulations (CFR) 21, Part 11.
Full CRO Solutions
Ockham offers complete Data and Clinical CRO services, including complete Phase I-IV Clinical Trial Management services, full-service or functionally based: Project Management, Clinical Monitoring, Data Management, Biostatistics and Programming, Medical Writing, Regulatory Consulting/Liaison, and PVG:
Clinical Project Management
- Investigator site selection
- Investigator grant negotiation and payment
- Site Regulatory Packet, Review and Approval
|
- Oversight of Clinical Research Associates (CRA)
- Review and Approval of Monitoring Visit Reports
- CRA Training and Co-monitoring
|
Clinical Monitoring
- Site qualification visits
- Regulatory documentation collection
- Site initiation visits
- Interim site visits
|
- Query management
- Site close-out visits
- Overall site management
|
Pharmacovigilance
- Around-the-clock, continuous physician coverage
- Serious Adverse Event (SAE) processing
- Investigator Letters, IND Reports
|
- SAE narratives, MedWatch, Analysis of Similar Events (AOSE)
- FDA reporting of SAEs
|
Data Management
- CRF/eCRF design
- Database design and programming
- Data coding
- EDC system set-up
|
- EDC User Acceptance Testing (UAT) and Reporting
- Validation
- Query management
- Data archiving
|
Biostatistics
- Full support for Phase I-IV clinical trials
- Optimal clinical trial study designs to meet regulatory and promotional needs
- Statistical analysis support for studies
- Table / Listing production and QC
|
- Expert consultation for statistical issues
- Study design and consultation
- Analysis plan development
- Interim analysis/DSMB
- Regulatory and advisory meeting support
|
Medical Writing / Regulatory
- Clinical protocols
- Summary sections of INDs and NDAs
- FDA pre-meeting packages
- Advisory Committee meeting briefing documents
- IND/ NDA preparation
|
- Integrated summaries of efficacy and safety
- Regulatory strategy documents
- Integrated clinical study reports
- FDA meeting minutes
|
Back to Top